NYSE$EHC
Encompass Health Corp · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Encompass Health reported Q3 2025, revenue of $1.48B, net income of $174.6M, diluted EPS of $1.24.
For Q3 2025, Encompass Health reported revenue of $1.48B, net income of $174.6M, diluted EPS was $1.24. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Revenue $1.48B.
- Net income $174.6M.
- Diluted EPS $1.24.
Headline financials
Revenue & EPS history
Encompass Health · Revenue · Quarterly
$1.48B
Forward guidance
The release discusses Encompass Health's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Encompass Health cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+1.2%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+2.5%
Avg return
30 days after
64%
42 / 66 earnings
Positive
+11.8%
Q1 2025
Best reaction
-9.0%
Q1 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.1% | +5.0% | +6.0% | |
| Q4 2025 | +5.9% | +13.9% | +7.4% | |
| Q3 2025 | -6.9% | -6.8% | -7.5% | |
| Q1 2025 | +11.8% | +15.4% | +17.2% | |
| Q4 2024 | +1.3% | -0.6% | +0.7% | |
| Q3 2024 | +7.0% | +5.8% | +10.0% | |
| Q2 2024 | -8.7% | -7.5% | +1.0% | |
| Q1 2024 | +0.3% | +1.4% | +2.5% | |
| Q4 2023 | +1.7% | +1.9% | +5.9% | |
| Q3 2023 | -1.9% | +0.9% | +6.7% | |
| Q2 2023 | +5.0% | +6.4% | +7.6% | |
| Q1 2023 | +0.7% | -0.6% | -5.9% | |
| Q4 2022 | +1.6% | +3.1% | -9.1% | |
| Q3 2022 | +6.4% | +11.1% | +16.6% | |
| Q2 2022 | +0.6% | +4.5% | -4.0% | |
| Q1 2022 | +2.6% | +2.5% | -2.0% | |
| Q4 2021 | +1.5% | -2.9% | +8.8% | |
| Q3 2021 | -6.0% | -5.8% | -9.8% | |
| Q2 2021 | +0.7% | +3.5% | -4.1% | |
| Q1 2021 | -1.6% | -2.7% | -2.5% | |
| Q4 2020 | -3.9% | -6.2% | -6.1% | |
| Q3 2020 | -2.6% | -3.0% | +25.9% | |
| Q2 2020 | +4.5% | +3.1% | -6.4% | |
| Q1 2020 | -1.1% | -7.1% | +6.4% | |
| Q4 2019 | +0.4% | +3.1% | -2.6% | |
| Q3 2019 | -5.8% | +2.0% | +5.5% | |
| Q2 2019 | -4.0% | -7.4% | -12.6% | |
| Q1 2019 | +5.3% | +3.6% | -4.6% | |
| Q4 2018 | -4.4% | -3.5% | -13.3% | |
| Q3 2018 | -5.7% | -4.0% | +1.4% | |
| Q2 2018 | +8.8% | +5.9% | +17.4% | |
| Q1 2018 | +7.2% | +7.3% | +10.3% | |
| Q4 2017 | +3.0% | +3.9% | +7.7% | |
| Q3 2017 | +1.8% | +2.0% | +8.7% | |
| Q2 2017 | +1.9% | -0.2% | +3.6% | |
| Q1 2017 | +7.9% | +10.0% | +6.3% | |
| Q4 2016 | +0.1% | +0.5% | -1.9% | |
| Q3 2016 | +1.8% | +0.7% | +5.6% | |
| Q2 2016 | +6.7% | +3.1% | -0.3% | |
| Q1 2016 | +10.9% | — | — | |
| Q4 2015 | +9.2% | — | — | |
| Q3 2015 | -0.3% | — | — | |
| Q2 2015 | -2.9% | — | — | |
| Q1 2015 | -9.0% | — | — | |
| Q4 2014 | -4.7% | — | — | |
| Q3 2014 | -3.0% | — | — | |
| Q2 2014 | +7.4% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q4 2013 | -2.8% | — | — | |
| Q3 2013 | +0.6% | — | — | |
| Q2 2013 | +4.7% | — | — | |
| Q1 2013 | +3.1% | — | — | |
| Q4 2012 | +7.2% | — | — | |
| Q3 2012 | +2.5% | — | — | |
| Q2 2012 | -3.7% | — | — | |
| Q1 2012 | +9.2% | — | — | |
| Q4 2010 | +3.9% | — | — | |
| Q4 2011 | +3.9% | — | — | |
| Q3 2011 | -1.0% | — | — | |
| Q2 2011 | -9.0% | — | — | |
| Q1 2010 | +0.4% | — | — | |
| Q1 2011 | +2.5% | — | — | |
| Q4 2008 | +7.8% | — | — | |
| Q3 2010 | +2.2% | — | — | |
| Q2 2010 | -1.0% | — | — | |
| Q4 2009 | -1.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro